RSV Protection Vaccine
Respiratory Syncytial Virus (RSV) · RSV bronchiolitis · RSV pneumonia
RSV is the leading cause of infant hospitalization in the US — responsible for 58,000–80,000 hospitalizations and 100–300 infant deaths annually. Nearly all children are infected by age 2. In most, it causes a cold. In the youngest infants, it can progress to severe bronchiolitis requiring oxygen, IV fluids, and ICU care. Former premature infants and those with cardiac or pulmonary conditions are at highest risk.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →Worth careful consideration. Disease risk in your scenario is lower than average, or the vaccine risk/uncertainty is somewhat higher. Discuss timing and priorities with your provider.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
RSV is the leading cause of infant hospitalization in the US — responsible for 58,000–80,000 hospitalizations and 100–300 infant deaths annually. Nearly all children are infected by age 2. In most, it causes a cold. In the youngest infants, it can progress to severe bronchiolitis requiring oxygen, IV fluids, and ICU care. Former premature infants and those with cardiac or pulmonary conditions are at highest risk.
Severe RSV bronchiolitis is distressing for both infants and parents — infants struggle to breathe and feed, sometimes requiring 5–10 days of hospitalization. Long-term: RSV is associated with increased risk of recurrent wheezing and asthma in childhood, though causation vs. correlation is debated.
🛡️ Vaccine Effectiveness
Nirsevimab (monoclonal antibody) provides protection for the entire RSV season (approximately 5 months). It is not a vaccine — it provides passive immunization. Annual administration at the start of each RSV season may be needed until the child's immune system matures. Maternal Abrysvo vaccine provides protection through maternal antibodies for approximately 3–6 months post-birth.
Protection is not complete — some breakthrough RSV infections occur, but hospitalizations are substantially reduced. First RSV season is highest risk.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Infants born April–September: administer nirsevimab when RSV season begins. Preterm infants in their second RSV season who remain high-risk may receive additional dosing per provider guidance.
⚖️ Benefits vs. Considerations
✓ Benefits
- RSV is the #1 reason infants are hospitalized — this directly addresses a major unmet need
- Phase 3 trial showed 80% reduction in RSV hospitalizations
- Monoclonal antibody (not a live vaccine) — especially suitable for premature infants and immunocompromised
- No 'active' immune response required — works immediately, unlike traditional vaccines
- Maternal vaccination option means protection from birth without an infant injection
↕ Considerations
- Very new product — only 2 years of post-approval safety data
- Not a traditional vaccine — requires annual administration as passive immunization
- Preterm birth signal from maternal Abrysvo trial — ongoing monitoring and FDA advisory
- Supply and cost challenges — new to immunization schedule
- 75–80% effectiveness means substantial RSV disease still occurs
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- The FDA approved Abrysvo despite a numerical imbalance in preterm births in the trial (5.7% vs 4.7%), and the FDA's Vaccines and Related Biological Products Advisory Committee voted 10–4 that the preterm birth signal did not outweigh benefits. Four dissenting votes from an FDA advisory committee is notable and uncommon — the minority argued that restricting to 32–36 weeks (rather than earlier) was insufficient mitigation (FDA VRBPAC, 2023).
- Nirsevimab is a monoclonal antibody, not a traditional vaccine — its annual administration requirement and cost raise sustainability questions for universal programs in lower-income settings or Medicaid-reliant systems where reimbursement pathways are still being established.
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- The preterm birth imbalance observed in the Abrysvo trial (5.7% vs 4.7% in placebo) requires ongoing monitoring — causal mechanism unclear, but FDA added it to prescribing information
- Long-term impact on RSV immunity development in infants who receive passive antibody protection — does it delay but not eliminate susceptibility?
- Cost-effectiveness at population scale, particularly for nirsevimab which requires annual administration
- Optimal strategy: maternal vaccine vs. infant monoclonal antibody — not yet resolved by evidence
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.